[go: up one dir, main page]

Chen et al., 2022 - Google Patents

cGAS-STING-mediated IFN-I response in host defense and neuroinflammatory diseases

Chen et al., 2022

View PDF
Document ID
11373205128810666668
Author
Chen K
Lai C
Su Y
Bao W
Yang L
Xu P
Zhu L
Publication year
Publication venue
Current neuropharmacology

External Links

Snippet

The presence of foreign or misplaced nucleic acids is a dangerous signal that triggers innate immune responses by activating cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) and binding to its downstream signaling effector stimulator of interferon genes (STING) …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Chen et al. cGAS-STING-mediated IFN-I response in host defense and neuroinflammatory diseases
Broekaart et al. Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood‐brain barrier dysfunction and seizure progression
Caggiu et al. Inflammation, infectious triggers, and Parkinson's disease
Milovanovic et al. Interleukin-17 in chronic inflammatory neurological diseases
Cox et al. DNA sensors are expressed in astrocytes and microglia in vitro and are upregulated during gliosis in neurodegenerative disease
Squillace et al. Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions
Romero‐Miguel et al. Minocycline in neurodegenerative and psychiatric diseases: an update
Barclay et al. Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)
Klein et al. Infectious immunity in the central nervous system and brain function
Chen et al. Microglia activation, classification and microglia-mediated neuroinflammatory modulators in subarachnoid hemorrhage
Banjara et al. Sterile neuroinflammation and strategies for therapeutic intervention
Zhang et al. Inborn errors of interferon (IFN)‐mediated immunity in humans: insights into the respective roles of IFN‐α/β, IFN‐γ, and IFN‐λ in host defense
Lin et al. INPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease
Kalinke et al. Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17‐mediated autoimmunity in the CNS
Wang et al. Inhibition of A1 astrocytes and activation of A2 astrocytes for the treatment of spinal cord injury
Xu et al. Ripks and neuroinflammation
Medvedeva et al. Semax, an analog of ACTH (4− 7), regulates expression of immune response genes during ischemic brain injury in rats
Kaur et al. Intracellular DAMPs in neurodegeneration and their role in clinical therapeutics
WO2017096963A1 (en) Use of agonist of stimulator of interferon genes in treating alzheimer's disease
Chaudhury et al. COVID-19 and central nervous system interplay: A big picture beyond clinical manifestation
Wang et al. Myricetin suppresses traumatic brain injury-induced inflammatory response via EGFR/AKT/STAT pathway
Mielcarska et al. Disrupting neurons and glial cells oneness in the brain—the possible causal role of herpes simplex virus type 1 (HSV-1) in Alzheimer’s disease
Sheng et al. IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential
Herzberg et al. Chronic inflammatory lameness increases cytokine concentration in the spinal cord of dairy cows
Kim et al. Therapeutic potential of exercise-hormone irisin in Alzheimer’s disease